Clinical Trial Update: Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial comparing dosing regimens of ISV-303 (bromfenac in DuraSite) to Xibrom and vehicle in ocular inflammation following cataract surgery; complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Inflammation
• Postoperative Ocular Inflammation

Drugs mentioned

• ISV-303 (bromfenac in DuraSite) (bromfenac)
• Xibrom (bromfenac)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Ocular Inflammation | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-07-13